Cargando…

Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

BACKGROUND: (18)F-fluorodeoxyglucose-positron emission tomography (PET)/computed tomography is useful in diagnosing lymph node and distant metastases of esophageal cancer. However, its value for predicting survival is controversial. AIM: To evaluate the value of PET complete metabolic response (CMR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kosuke, Etoh, Tsuyoshi, Shibata, Tomotaka, Nishiki, Kohei, Fumoto, Shoichi, Ueda, Yoshitake, Shiroshita, Hidefumi, Shiraishi, Norio, Inomata, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085515/
https://www.ncbi.nlm.nih.gov/pubmed/33959478
http://dx.doi.org/10.5306/wjco.v12.i4.249
_version_ 1783686357398323200
author Suzuki, Kosuke
Etoh, Tsuyoshi
Shibata, Tomotaka
Nishiki, Kohei
Fumoto, Shoichi
Ueda, Yoshitake
Shiroshita, Hidefumi
Shiraishi, Norio
Inomata, Masafumi
author_facet Suzuki, Kosuke
Etoh, Tsuyoshi
Shibata, Tomotaka
Nishiki, Kohei
Fumoto, Shoichi
Ueda, Yoshitake
Shiroshita, Hidefumi
Shiraishi, Norio
Inomata, Masafumi
author_sort Suzuki, Kosuke
collection PubMed
description BACKGROUND: (18)F-fluorodeoxyglucose-positron emission tomography (PET)/computed tomography is useful in diagnosing lymph node and distant metastases of esophageal cancer. However, its value for predicting survival is controversial. AIM: To evaluate the value of PET complete metabolic response (CMR) as a prognostic predictor for esophageal cancer. METHODS: Between June 2013 and December 2017, 58 patients with squamous cell esophageal cancer who underwent neoadjuvant chemotherapy (NAC) in Oita University were enrolled in this retrospective cohort study. Tumors were clinically staged using fluorodeoxyglucose-PET/computed tomography before and after NAC. After NAC, maximal standardized uptake value ≤ 2.5 was defined as PET-CMR, and maximal standardized uptake value > 2.5 was defined as non-PET-CMR. We compared short-term outcomes between the PET-CMR group and non-PET-CMR group and evaluated prognostic factors by univariate and multivariate analyses. RESULTS: The PET-CMR group included 22 patients, and the non-PET-CMR group included 36 patients. There were no significant differences in intraoperative and postoperative complications between the two groups. Five-year relapse-free survival and overall survival in the PET-CMR group were significantly more favorable than those in the non-PET-CMR group (38.6 mo vs 20.8 mo, P = 0.021; 42.8 mo vs 25.1 mo, P = 0.011, respectively). PET-CMR was a significant prognostic factor in terms of relapse-free survival by univariate analysis (hazard ratio: 2.523; 95% confidence interval: 1.034–7.063; P < 0.041). Particularly, PET-computed tomography negative N was an independent prognostic factor of relapse-free survival and overall survival by multivariate analysis. CONCLUSION: PET-CMR after NAC is considered a favorable prognostic factor for esophageal cancer. Evaluation by PET-computed tomography could be useful in clinical decision making for esophageal cancer.
format Online
Article
Text
id pubmed-8085515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-80855152021-05-05 Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil Suzuki, Kosuke Etoh, Tsuyoshi Shibata, Tomotaka Nishiki, Kohei Fumoto, Shoichi Ueda, Yoshitake Shiroshita, Hidefumi Shiraishi, Norio Inomata, Masafumi World J Clin Oncol Retrospective Cohort Study BACKGROUND: (18)F-fluorodeoxyglucose-positron emission tomography (PET)/computed tomography is useful in diagnosing lymph node and distant metastases of esophageal cancer. However, its value for predicting survival is controversial. AIM: To evaluate the value of PET complete metabolic response (CMR) as a prognostic predictor for esophageal cancer. METHODS: Between June 2013 and December 2017, 58 patients with squamous cell esophageal cancer who underwent neoadjuvant chemotherapy (NAC) in Oita University were enrolled in this retrospective cohort study. Tumors were clinically staged using fluorodeoxyglucose-PET/computed tomography before and after NAC. After NAC, maximal standardized uptake value ≤ 2.5 was defined as PET-CMR, and maximal standardized uptake value > 2.5 was defined as non-PET-CMR. We compared short-term outcomes between the PET-CMR group and non-PET-CMR group and evaluated prognostic factors by univariate and multivariate analyses. RESULTS: The PET-CMR group included 22 patients, and the non-PET-CMR group included 36 patients. There were no significant differences in intraoperative and postoperative complications between the two groups. Five-year relapse-free survival and overall survival in the PET-CMR group were significantly more favorable than those in the non-PET-CMR group (38.6 mo vs 20.8 mo, P = 0.021; 42.8 mo vs 25.1 mo, P = 0.011, respectively). PET-CMR was a significant prognostic factor in terms of relapse-free survival by univariate analysis (hazard ratio: 2.523; 95% confidence interval: 1.034–7.063; P < 0.041). Particularly, PET-computed tomography negative N was an independent prognostic factor of relapse-free survival and overall survival by multivariate analysis. CONCLUSION: PET-CMR after NAC is considered a favorable prognostic factor for esophageal cancer. Evaluation by PET-computed tomography could be useful in clinical decision making for esophageal cancer. Baishideng Publishing Group Inc 2021-04-24 2021-04-24 /pmc/articles/PMC8085515/ /pubmed/33959478 http://dx.doi.org/10.5306/wjco.v12.i4.249 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Suzuki, Kosuke
Etoh, Tsuyoshi
Shibata, Tomotaka
Nishiki, Kohei
Fumoto, Shoichi
Ueda, Yoshitake
Shiroshita, Hidefumi
Shiraishi, Norio
Inomata, Masafumi
Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title_full Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title_fullStr Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title_full_unstemmed Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title_short Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
title_sort positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085515/
https://www.ncbi.nlm.nih.gov/pubmed/33959478
http://dx.doi.org/10.5306/wjco.v12.i4.249
work_keys_str_mv AT suzukikosuke positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT etohtsuyoshi positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT shibatatomotaka positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT nishikikohei positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT fumotoshoichi positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT uedayoshitake positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT shiroshitahidefumi positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT shiraishinorio positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil
AT inomatamasafumi positronemissiontomographycompletemetabolicresponseasafavorableprognosticpredictorinesophagealcancerfollowingneoadjuvantchemotherapywithdocetaxelcisplatin5fluorouracil